Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

Abstract

Despite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a PPPGA of 0/1, the presence of significant differences observed for several secondary endpoints suggests that apremilast may have a role in the treatment of moderate-to-severe palmoplantar psoriasis.